arrow_back Back Filing freshness 10-Q Q2 FY2025 SEC EDGAR

LISATA THERAPEUTICS, INC.

LSTA
$1.01 ▼ -0.07 (-6.48%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
67 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
23
Health
Poor
Bearish
auto_awesome

Analytical Summary

LISATA THERAPEUTICS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $9.2M
Dividend Yield —
Revenue Growth N/M
Op. Margin None
ROIC -54.8% ↘
FCF / Share $-0.29 ↗
Trailing P/E —
Price / Book 1.1x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-2.93M
↑ +37.1% —
Operating Margin Operating profit as % of sales
-494.9%
↓ -311.4% —
FCF / Share Free cash flow per share
$-0.29
↑ +15.0% —
Long-Term Debt Long-term obligations
$0.00
— —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
7
Cash Quality ↑
63

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 17 years · 67 quarters